For the Inventor, By the Inventor

Enter assignee name

Grand Cayman, Cayman Islands

Dart Neuroscience, (cayman) Ltd.

USPTO Granted Patents = 41

Forward Citations = 53

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Alan P Kaplan (23 out of 30 patents)

James Breitenbucher (13 out of 19 patents)

Troy Vickers (12 out of 15 patents)

4. Laurent Gomez (11 out of 29 patents)

5. Terence P Keenan (11 out of 23 patents)

6. Varsha Gupta (9 out of 12 patents)

7. Graeme Freestone (8 out of 8 patents)

8. Tami Jo Marrone (8 out of 8 patents)

9. Andrew Richard Hudson (8 out of 17 patents)

10. Robert Huerta Lemus (7 out of 18 patents)

11. Brian Dyck (7 out of 28 patents)

12. Andrew J McRiner (7 out of 18 patents)

13. Marco Peters (7 out of 10 patents)

14. Rusiko Bourtchouladze (7 out of 14 patents)

15. Michael I Weinhouse (7 out of 12 patents)

41 patents: Sort by Forward Citations

1. 11186582 - Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors (2021-11-30),

2. 10501465 - Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors (2019-12-10),

3. 10376514 - Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones (2019-08-13),

4. 10239882 - Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors (2019-03-26),

5. 10105367 - Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones (2018-10-23),

6. 10092575 - Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds (2018-10-09),

7. 10053467 - Therapeutic isoxazole compounds (2018-08-21),

8. 10040759 - Substituted azetidinyl compounds as GlyT1 inhibitors (2018-08-07),

9. 9956213 - Substituted naphthyridine and quinoline compounds as MAO inhibitors (2018-05-01),

10. 9932345 - Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors (2018-04-03),

11. 9931318 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation (2018-04-03),

12. 9863934 - Screening methods for cognitive enhancers (2018-01-09),

13. 9795591 - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation (2017-10-24),

14. 9708334 - Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors (2017-07-18),

15. 9675605 - Substituted naphthyridine and quinoline compounds as MAO inhibitors (2017-06-13),

Dart Neuroscience, (Cayman) LTD. is a research-based biotech company that focuses on developing innovative drugs for neurological disorders. With a team of experienced scientists and researchers, Dart Neuroscience is committed to advancing the understanding of brain function and discovering breakthrough treatments. Their cutting-edge research programs aim to address conditions such as Alzheimer's disease, Parkinson's disease, and depression. Visit their website to learn more about their pioneering work in neuroscience.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

41 Patents

#26 in Grand Cayman

#32 in Cayman Islands

#16,187 in the World

Grand Cayman, Cayman Islands

Dart Neuroscience, (cayman) Ltd.

Forward Citations = 53

46 inventors:

Alan P Kaplan (23 out of 30 patents)

James Breitenbucher (13 out of 19 patents)

Troy Vickers (12 out of 15 patents)

4. Laurent Gomez (11 out of 29 patents)

5. Terence P Keenan (11 out of 23 patents)

Please report any incorrect information to support@idiyas.com

Loading…